Biogen (BIIB) Current Deferred Revenue (2010 - 2012)

Biogen (BIIB) posted quarterly Current Deferred Revenue of $110.3 million for Q2 2012, up 14.9% quarter-over-quarter from $96.0 million in Q1 2012.

Biogen (BIIB) Current Deferred Revenue (2010 - 2012) Analysis & Trends

Biogen's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $110.3 million for Q2 2012.

In Q2 2012, Current Deferred Revenue changed N/A year-over-year to $110.3 million; the TTM figure through Jun 2012 stood at $110.3 million (changed N/A YoY), while the FY2011 annual figure was $69.6 million, up 68.52% from the prior year.
Current Deferred Revenue for Q2 2012 stood at $110.3 million, up from $96.0 million in the prior quarter.
The five-year high for Current Deferred Revenue was $110.3 million in Q2 2012, with the low at $41.3 million in Q4 2010.
The 3-year median for Current Deferred Revenue is $82.8 million (2011), against an average of $79.3 million.
Peak annual rise in Current Deferred Revenue reached 68.52% in 2011, while the deepest fall reached 68.52% in 2011.
Biogen's Current Deferred Revenue stood at $41.3 million in 2010, then soared by 68.52% to $69.6 million in 2011, then jumped by 58.48% to $110.3 million in 2012.
Business Quant data shows BIIB's Current Deferred Revenue at $110.3 million in Q2 2012, $96.0 million in Q1 2012, and $69.6 million in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Biogen	32.04 Bn	30.76 Bn	1.96 Bn

Download Data